Profile
PXMD NVO VRTX REGN SGEN MRNA
Company Name PaxMedica, Inc. Common Stock Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Moderna, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $5.15M $559.94B $104.59B $97.94B $43.15B $41.31B
Employees 0.01K 63.37K 5.40K 13.45K 3.26K 5.60K
CEO Mr. Howard J. Weisman Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Stephane Bancel
Ratings
PXMD NVO VRTX REGN SGEN MRNA
Quant Rating Score 2 5 5 5 3 4
Quant Rating Sell Strong Buy Strong Buy Strong Buy Neutral Buy
Trading
PXMD NVO VRTX REGN SGEN MRNA
Last Close $0.716 $128.64 $404.91 $907.32 $228.74 $107.89
High 52 $4.5 $199.54 $446.08 $993.35 $228.9 $138.14
Low 52 $0.17 $87.78 $323.3 $692.45 $187.64 $69.51
Price vs. 52 Week High -84.09 % -35.53 % -9.23 % -8.66 % -0.07 % -21.9 %
Price vs. 52 Week Low 321.18 % 46.55 % 25.24 % 31.03 % 21.9 % 55.22 %
Total Return
PXMD NVO VRTX REGN SGEN MRNA
1 Month Return 29.76 % -0.09 % -2.59 % -6.19 % 0 % 2.33 %
3 Month Return 42.89 % 22.27 % -5.3 % -4.32 % 0 % 6.71 %
6 Month Return 256.04 % 31.91 % 9.62 % 12.81 % 5.19 % 35.27 %
9 Month Return -16.74 % -20.63 % 13.4 % 24.78 % 16.57 % -12.29 %
YTD Return -5.42 % 24.35 % -0.49 % 3.31 % 0 % 8.49 %
1 Year Return -54.97 % -24.54 % 21.65 % 13.84 % 12.53 % -21.9 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
PXMD NVO VRTX REGN SGEN MRNA
Dividend Yield Percentage (TTM) - 1.41 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.54 % 10.64 % 5.88 % -3.35 % -3.75 %
Dividend Per Share (TTM) - 1.81 % - - - -
Payout Ratio (TTM) - 37.96 % 2.04 % - - -2.63 %
Growth
PXMD NVO VRTX REGN SGEN MRNA
Asset Growth 157.69 % 30.35 % 25.23 % 13.23 % -1.21 % -28.74 %
Gross Profit Growth - 32.32 % 9.25 % 6.49 % 22.93 % -85.12 %
Revenue Growth - 31.26 % 10.17 % 7.76 % 24.65 % -64.94 %
Revenue 3 Year - 90.51 % 59.87 % 56.27 % 91.84 % 2354.12 %
Revenue 5 Year - 124.2 % 218.58 % 97.36 % 215.48 % 1070.62 %
Revenue 10 Year - 66.11 % 608.27 % 509.63 % 494.04 % 6447.35 %
EBIT Growth -52.25 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Net Income Growth 3.71 % 50.71 % 8.96 % -8.87 % 9.51 % -156.37 %
Net Income 3 Yeari Growth Per Share -1197.84 % 106.79 % 34.59 % 13.92 % -764.83 % -529.35 %
Net Income 5 Yeari Growth Per Share - 133.86 % 70.33 % 63.31 % -276.93 % -160.17 %
Net Income 10 Yeari Growth Per Share - 98.61 % 809.6 % 811.34 % -624.16 % -2046.03 %
Operating Income Growth -52.25 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Operating Cash Flow Growth (CFG) -77.37 % 38.06 % -14.35 % -8.39 % 9.07 % -162.6 %
Operating 3 Year CFG -2661.71 % 118.29 % 9.63 % 77.63 % -148.34 % -253.42 %
Operating 5 Year CFG - 163.51 % 174.78 % 111.31 % -195.86 % -100.11 %
Operating 10 Year CFG - 150.92 % 5187.08 % 663.48 % -2622.09 % -4698.89 %
EPS Growth -406.91 % 52.28 % 8.33 % -8.54 % 10.81 % -158.04 %
EPS Diluted Growth -406.91 % 52.37 % 8.35 % -9.03 % 10.81 % -161.33 %
Book Value Per Share 16256.68 % 29 % 25.58 % 14.4 % -9.83 % -21.18 %
Share Holder 3 Year Equity Growth Per Share 540.55 % 75.22 % 104.06 % 138.48 % 33.92 % 439.47 %
Share Holder 5 Year Equity Growth Per Share - 121.9 % 291.14 % 199.46 % 220.81 % 92.24 %
Share Holder 10 Year Equity Growth Per Share - 49.62 % 1030.79 % 1201.51 % 691.19 % 1519.81 %
Dividend Per Share Growth 179435344.48 % 26.89 % - - - 59.65 %
Dividend 3 Year Growth Per Share - 64.4 % -100 % - - 3725.19 %
Dividend 5 Year Growth Per Share - 80.03 % -100 % - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -100 % 4.74 % 44.1 % 0.06 % -23.28 % 3.58 %
Free Cash Flow Growth -77.37 % 9.17 % -16.47 % -17.11 % 3.67 % -183.5 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
PXMD NVO VRTX REGN SGEN MRNA
Gross Profit Margin TTM - 84.6 % 87.21 % 87.87 % 75.4 % 31.49 %
Return on Assets TTM -318.48 % 26.61 % 15.92 % 11.95 % -20.64 % -25.58 %
Return on Equity TTM -946.38 % 90.49 % 22.62 % 16.07 % -28.06 % -29.87 %
Return on Capital Employed TTM -415.57 % 70.82 % 19.82 % 13.65 % -29.5 % -27.51 %
Net Income Per EBT TTM 98.91 % 79.95 % 82.64 % 94.15 % 101.53 % 119.58 %
EBT Per Ebit TTM 113.28 % 102.05 % 115.19 % 103.76 % 93.47 % 92.99 %
EBIT Per Revenue TTM - 44.16 % 38.53 % 30.85 % -34.37 % -61.88 %
Cash Flow To Debt Ratio TTM - 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Receivables Turnover TTM - 3.09 6.31 2.31 3.64 6.34
Payables Turnover TTM - 1.4 3.46 2.62 2.52 9.03
Inventory Turnover TTM - 1.12 1.71 0.62 1.07 23.23
Fixed Asset Turnover TTM - 255.34 % 679.28 % 316.35 % 471.71 % 257.71 %
Asset Turnover TTM - 73.85 % 43.42 % 39.65 % 63.3 % 37.18 %
Operating Cash Flow Per Share TTM -1.45 24.39 13.73 43.1 -2.87 -8.18
Free Cash Flow Per Share TTM -1.45 15.68 12.72 35.77 -3.73 -10.04
Cash Per Share TTM 63.65 % 677.09 % 4354.48 % 10173.36 % 657.5 % 2258.27 %
Operating Cash Flow Sales Ratio TTM - 46.89 % 35.84 % 35.02 % -23.48 % -45.52 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 64.29 % 92.69 % 83.01 % 129.82 % 122.67 %
Cash Flow Coverage Ratios TTM - 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Price To Free Cash Flows Ratio TTM -0.48 55.82 31.9 25.68 -61.54 -10.8
Price To Operating Cash Flows Ratio TTM -0.47 36.81 29.5 21.05 -79.67 -13.18
Price Cash Flow Ratio TTM -0.47 36.81 29.5 21.05 -79.67 -13.18
Income Statement (TTM)
PXMD NVO VRTX REGN SGEN MRNA
Revenue $0B $232.26B $9.84B $13.12B $1.96B $6.75B
Gross Profit $0B $196.5B $8.58B $11.3B $1.55B $2.06B
Gross Profit Ratio 0% 84.6% 87.17% 86.16% 79.1% 30.52%
EBITDA $-0.02B $112.94B $3.93B $5.13B $-0.62B $-3.21B
Net Income $-0.02B $83.68B $3.62B $3.95B $-0.61B $-4.71B
EPS Diluted -11 18.62 13.89 34.77 -3.3 -12.34
Balance Sheet (MRQ)
PXMD NVO VRTX REGN SGEN MRNA
Long Term Debt $0B $20.53B $0.72B $2.7B $0.04B $1.22B
Total Liabilities $0B $207.93B $5.15B $7.11B $0.87B $4.57B
Total Equity $0B $106.56B $17.58B $25.97B $2.8B $13.85B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $4.68B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $1.24B
Total Assets $0.01B $314.49B $22.73B $33.08B $3.67B $18.43B
Cash Flow Statement (TTM)
PXMD NVO VRTX REGN SGEN MRNA
Net Income $-0.02B $83.68B $3.62B $3.95B $-0.61B $-4.71B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $0.75B
Dividends Paid $-11.95B $-31.77B $0B $0B $0B $-0.27B
Operating Cash Flow $-0.01B $108.91B $3.54B $4.59B $-0.45B $-3.12B
Capital Expenditure $0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.71B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.81
ABCL AbCellera Biologics Inc. 4.1001
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 3.26
ABIO ARCA biopharma, Inc. 3.7022
ABOS Acumen Pharmaceuticals, Inc. 3.185
ABSI Absci Corporation 4.76
ABUS Arbutus Biopharma Corporation 2.76
ABVC ABVC BioPharma, Inc. 1.4699
ABVX Abivax SA American Depositary Shares 16.05
ACAD ACADIA Pharmaceuticals Inc. 16.715
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.985
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.793
ACHV Achieve Life Sciences, Inc. 4.52
ACIU AC Immune SA 2.44
ACLX Arcellx, Inc. 54.37
ACRV Acrivon Therapeutics, Inc. Common Stock 9.64
ACST Acasti Pharma Inc. 2.88
ETFs With Exposure to PXMD
Ticker ETF Name Weight Percentage Price
VXF Vanguard Extended Market Index Fund 0 166.75
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 126.2
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 126.21
VEMPX Vanguard Extended Market Index InstlPlus 0 311.45
Unlock